Leader Capital Holdings Stock (OTC: LCHD)

Leader Capital Holdings (OTC:LCHD) Stock, Quote.Headers.trade-ideas

Leader Capital Holdings Corp through its subsidiaries owns and operates a mobile application platform that connects the investor with other financial service providers. The company's application helps to meet the generic needs of financial service providers mainly for trust and insurance companies. Investors can use this platform to make their investment decisions in real-time and place investment orders without having to e-mail or fax documents to their investment advisor. The Company operates in one business and industry segment: the provision of investment platform services through mobile application.

LEADER CAPITAL HLDGS CP by Leader Capital Holdings Corp.

Leader Capital Holdings Corp

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Morgan Stanley analyst Betsy Graseck downgraded the rating for Bank of America Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) from Overweight to Equal-Weight but raised the price target from $48 to $55. Bank of America shares closed at $46.75 on Friday. See how other analysts view this stock.</li>
<li>Leerink Partners analyst Puneet Souda downgraded Myriad Genetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) from Outperform to Market Perform and slashed the price target from $30 to $21. Myriad Genetics shares closed at $15.13 on Friday. <a href="https://www.benzinga.com/quote/MYGN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Michael Yee downgraded the rating for Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) from Buy to Hold and lowered the price target from $250 to $180. Biogen shares closed at $157.78 on Friday. See how other analysts view this stock.</li>
<li>B of A Securities analyst Vivek Arya downgraded Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) from Buy to Neutral and lowered the price target from $180 to $155. AMD shares closed at $138.59 on Friday. <a href="https://www.benzinga.com/quote/AMD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Sandeep Deshpande downgraded the rating for STMicroelectronics N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>) from Overweight to Neutral. STMicroelectronics shares closed at $26.43 on Friday. <a href="https://www.benzinga.com/quote/STM/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying AMD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="616" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/09082137/image-64-1024x616.png" alt="" class="wp-image-683191" style="width:572px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/09082137/image-64-1024x616.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/09082137/image-64-300x180.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/09082137/image-64-768x462.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/09082137/image-64.png 1093w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/12/42380712/how-to-earn-500-a-month-from-oracle-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Oracle Stock Ahead Of Q2 Earnings</a></li>
</ul>

News

Downgrades

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

BIIB

MYGN

This AMD Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

Barclays analyst Benjamin Budish maintains CME Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>) with a Equal-Weight and raises the price target from $231 to $257.

Price Target

Barclays Maintains Equal-Weight on CME Gr, Raises Price Target to $257

Biotech

General

LTRN

Lantern Pharma Enrolls First Patient In Taiwan For Phase 2 HARMONIC Trial Of LP-300 Targeting Never-Smoker NSCLC Patients, Highlighting Taiwan Expansion Where Over 50% Of Lung Cancer Cases Occur In Never-Smokers, With Active Screening At Multiple Sites

Contracts

AMTM

Amentum Announces $105M Research, Development, Test And Evaluation Contract Contract To Support Naval Surface Warfare Center Crane Airborne Electronic Attack Systems Division

WIIM

Kanzhun shares are trading lower after Bernstein downgraded the stock from Outperform to Market Perform and cut its price target from $19 to $15.

<a href="https://www.globenewswire.com/Tracker?data=9eXdzZima7MtBYbU7nVdEKxbdF3oNK61WHDEu_WMNXUnj_5IUI24hF31YrtsVc97kW7kOqfEuupjNQJtgN7kMq5Dmfk-MOeUKnxjWmTEIT0=">Atossa Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOS#NASDAQ">ATOS</a>) ("Atossa" or the "Company"), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced the presentation of research investigating the anti-cancer activity of (Z)-endoxifen and its byproducts at the American Association for Cancer Research (AACR) Special Conference in Cancer Research, taking place in Toronto from December 9-11.&nbsp;
The poster, titled,&nbsp;"Anti-cancer activity of (Z)-endoxifen-related compounds in ERα+ breast cancer,"&nbsp;outlines results from a study investigating four (Z)-endoxifen byproducts for their anti-estrogenic and anti-tumor effects in estrogen receptor-positive (ERα+) breast cancer cell lines, including those with ESR1 mutations (Y537S and D538G) associated with endocrine resistance. Notably, compounds AT416E and AT402E demonstrated strong anti-proliferative activity, with AT416E also showing enhanced inhibition of cell migration and invasion. All four byproducts exhibited greater anti-proliferative effects than (Z)-endoxifen in estrogen-deficient conditions, while (Z)-endoxifen remained the most potent at inducing cell cycle arrest and apoptosis, reinforcing its potential as a therapeutic agent.

ATOS

Atossa Therapeutics Presents Data From Study Investigating Anti-Cancer Activity Of (Z)-Endoxifen-Related Compounds At AACR Special Conference In Cancer Research

Barclays analyst Lauren Lieberman maintains Brown-Forman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) with a Overweight and raises the price target from $49 to $51.

BF/B

Barclays Maintains Overweight on Brown-Forman, Raises Price Target to $51

Amentum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMTM#NYSE">AMTM</a>) has been awarded a $105 million contract to support <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.navsea.navy.mil%2FHome%2FWarfare-Centers%2FNSWC-Crane%2FWhat-We-Do%2FElectronicWarfare%2F&amp;esheet=54163296&amp;newsitemid=20241209601699&amp;lan=en-US&amp;anchor=Naval+Surface+Warfare+Center+Crane+%28NSWC+Crane%29&amp;index=1&amp;md5=f119fb6c353521b0b566daf285ed3a66">Naval Surface Warfare Center Crane (NSWC Crane)</a> Airborne Electronic Attack Systems Division (AEASD) to develop the next generation of Electronic Warfare (EW) and Intelligence, Surveillance, and Reconnaissance (ISR) mission and survivability systems. Amentum will replace aging or obsolete components and systems and install state-of-the-art technology to enhance the capabilities of EW and ISR systems, delivering critical expertise in <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.amentum.com%2Fnavy-marine-corps%2F&amp;esheet=54163296&amp;newsitemid=20241209601699&amp;lan=en-US&amp;anchor=protecting+U.S.+national+security&amp;index=2&amp;md5=1a08994ab151ef992c503d883447aa9d">protecting U.S. national security</a>.

Amentum Awarded $105M Research, Development, Test And Evaluation Contract To Enhance Electronic Warfare Systems

SATL

Satellogic Announces $10M Private Placement With Single Institutional Investor, Issuing 3.57M Class A Shares At $2.80 Each; Proceeds To Support General Corporate Purposes With Closing Expected By December 10, 2024

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Monday.
Shares of BioAge Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOA#NASDAQ">BIOA</a>) fell sharply in today's pre-market trading after the company announced discontinuation of STRIDES Phase 2 clinical trial evaluating Azelaprag in combination with Tirzepatide <a href="https://www.benzinga.com/quote/BIOA/news">for the treatment of obesity.</a>
BioAge Labs shares tumbled 68.6% to $6.30 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Palmer Square Capital BDC Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSBD#NASDAQ">PSBD</a>) shares tumbled 18.3% to $13.00 in pre-market trading.</li>
<li>Bicara Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAX#NASDAQ">BCAX</a>) fell 14.7% to $18.00 in pre-market trading after gaining 8% on Friday.</li>
<li>ZJK Industrial Co Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJK#NASDAQ">ZJK</a>) fell 10.9% to $12.55 in pre-market trading.</li>
<li>Heritage Commerce Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTBK#NASDAQ">HTBK</a>) declined 9.7% to $9.50 in pre-market trading.</li>
<li>Bel Fuse Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BELFB#NASDAQ">BELFB</a>) declined 7.1% to $78.00 in pre-market trading.</li>
<li>Riot Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) fell 6.7% to $12.08 in pre-market trading. Riot Platforms announced a proposed private offering of $500 million of convertible senior notes.</li>
<li>ZimVie Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZIMV#NASDAQ">ZIMV</a>) fell 6.5% to $13.03 in pre-market trading.</li>
<li>AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) declined 5.8% to $378.00 in pre-market trading after gaining around 6% on Friday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/12/42380712/how-to-earn-500-a-month-from-oracle-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Oracle Stock Ahead Of Q2 Earnings</a></li>
</ul>

BCAX

BELFB

BIOA

HTBK

PSBD

RIOT

ZIMV

BioAge Labs, Riot Platforms And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Syntec Optics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTX#NASDAQ">OPTX</a>), a leading provider of mission-critical products to advanced technology defense, biomedical, and communications equipment manufacturers, today announced that it has secured over $2.1 million in orders for its ultra-high-precision space optics. The company will utilize its dedicated production cell to continue delivering products.

OPTX

Syntec Optics Secures $2.1M In New Orders For Space Optics

Ocean Power Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OPTT#NYSE">OPTT</a>) ("OPT" or the "Company"), a leader in innovative and cost-effective low-carbon marine power, data, and service solutions, today announced a new partnership, with $3M of purchase order commitments over 36 months in Latin America. This increases by $1.5M the previously announced $1.5M of purchases orders in Latin America.
The WAM-V USV's, renowned for their cutting-edge technology and versatility, will be deployed in hydrographic applications and by utilizing their adaptability and reliability will provide our customer with an unrivaled versatile multi-application solution. This landmark order not only underscores the growing demand for OPT's innovative solutions but also solidifies the Company's position as a leader in the maritime artificial intelligence robotics sector.

OPTT

Ocean Power Technologies Secures $3M In Purchase Order Commitments For WAM-V USV's In Latin America

QBTS

D-Wave Quantum Entered Sales Agreement With Needham, Roth Capital, And Craig-Hallum Pursuant To Which Co. May Sell From Time To Time Shares; Co. May Offer And Sell Shares Having Aggregate Offering Price Of Up To $75M

Barclays analyst Benjamin Budish maintains Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) with a Equal-Weight and raises the price target from $174 to $199.

Barclays Maintains Equal-Weight on Blackstone, Raises Price Target to $199

ACLX

Arcellx shares are trading higher after the company announced its cancer cell therapy showed a deep durable response with the management safety profile in heavily pretreated blood cancer patients.

Apollo Global Management, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) shares are trading higher premarket today. On Friday, S&amp;P Dow Jones Indices disclosed Apollo Global Management will join the S&amp;P 500, <a target="_blank" href="https://www.benzinga.com//node/42375634" rel="noreferrer noopener">effective December 23, 2024.</a>
In another development today, Apollo, along with Banco Santander, S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAN#NYSE">SAN</a>), disclosed that Apollo-managed funds and affiliates will invest in an around $370 million <a href="https://www.benzinga.com/pressreleases/24/12/g42383912/apollo-and-santander-partner-on-a-370-million-infrastructure-portfolio-financing" target="_blank" rel="noreferrer noopener">portfolio of infrastructure credit</a>.
The transaction was led by Apterra, an Apollo affiliate established in 2023, specializing in innovative financing solutions for infrastructure projects.
Apollo Partner and President of ACT Capital Samuel Feinstein said, &#8220;We have high conviction in the infrastructure finance opportunity globally given the large capital demands that will continue to drive investment in the sector and see continued opportunity to collaborate with Santander in the space.&#8221;
Over the past five years, Apollo has invested over $40 billion in energy transition and climate-related projects and aims to expand its platform as capital deployment in these sectors accelerates.
Across asset classes, Apollo targets $50 billion in clean energy and climate investments by 2027, with potential to exceed $100 billion by 2030.
Last week, Apollo agreed to acquire a 50% stake in a 2 GW Texas solar and battery energy storage <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42315021/apollo-funds-acquire-50-stake-in-2-gw-texas-solar-and-bess-portfolio-from-totalenergies" rel="noreferrer noopener">portfolio from </a><a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42315021/apollo-funds-acquire-50-stake-in-2-gw-texas-solar-and-bess-portfolio-from-totalenergies" rel="noreferrer noopener">TotalEnergies</a>.
The assets include three solar projects (1.7 GW) and two battery storage projects (300 MW) in the ERCOT market. TotalEnergies will retain a 50% stake and continue operating the assets.
Investors can gain exposure to the APO stock via&nbsp;EA Series Trust WHITEWOLF Publicly Listed Private Equity ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/LBO#BATS">LBO</a>) and&nbsp;Fidelity Disruptive Finance ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDFF#NASDAQ">FDFF</a>).
Price Action: APO shares are up 5.71% at $188.00 premarket at the last check Monday.
Image via Shutterstock.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/24/12/42378209/deal-dispatch-ubisoft-in-buyout-talks-dental-supplier-explores-sale-beloved-drive-through-goes-bankrupt" target="_blank" rel="noreferrer noopener">Deal Dispatch: Ubisoft In Buyout Talks, Dental Supplier Explores Sale, Beloved Drive-Through Goes Bankrupt</a></li>
</ul>

Equities

Large Cap

Financing

Movers

FDFF

Why Is Private Equity Giant Apollo Global Management Stock Shooting Higher Today?

StoneX Group Inc. (("StoneX", NASDAQ:<a href="https://www.benzinga.com/stock/SNEX#NASDAQ">SNEX</a>) announces changes to its executive management team. At its recently concluded meeting of the StoneX Board of Directors (the "Board"), several changes to StoneX's executive management team were approved. These changes include:
<ul>
<li>Sean O'Connor, StoneX's current Chief Executive Officer, will become Executive Vice-Chairman of the Board of Directors;</li>
<li>Philip Smith, currently a member of StoneX's executive committee responsible for the Commercial and Payments business segments, will become Group Chief Executive Officer; and</li>
<li>Charles Lyon, currently a member of StoneX's executive committee responsible for the Institutional business segment, will become Group President. &nbsp;</li>
</ul>
Mr. O'Connor will continue to be an active member of StoneX's executive committee with primary focus on longer-term strategy, capital allocation and M&amp;A activity, and his compensation package has been restructured to reflect a focus on share price appreciation and long-term value creation. Mr. Smith and Mr. Lyon will have general responsibility for managing StoneX's business and will report to Mr. O'Connor.

Management

SNEX

StoneX's Current CEO Sean O'Connor, Will Become Executive VC Of The Board Of Directors; Philip Smith, Will Become Group CEO; And Charles Lyon, Will Become Group President

ASTS

AST SpacemMbile shares are trading higher after the company announced a partnership with Vodafone for its global broadband connectivity through 203.4

Barclays analyst Benjamin Budish maintains BlackRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) with a Overweight and raises the price target from $1120 to $1220.

Barclays Maintains Overweight on BlackRock, Raises Price Target to $1220

Spotlight presentation using Guardant Reveal&#x2122; test suggests ctDNA has potential to predict sensitivity to endocrine therapy and long-term outcomes in HR+ breast cancer
Guardant Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>), a leading precision oncology company, today announced the company and its research collaborators will present data demonstrating the benefits of its precision oncology tests, real-world clinical-genomic database and AI analytics in optimizing therapy selection, identifying resistance mutations, and predicting long-term outcomes at the San Antonio Breast Cancer Symposium (SABCS) 2024 in San Antonio, Texas, Dec. 10-13, 2024.

Guardant Health To Share New Research Demonstrating Value Of Liquid Biopsy Tests, Real-world Data And AI Analytics In Tailoring Treatment Approaches For Breast Cancer At 2024 San Antonio Breast Cancer Symposium

Comments

Leader Capital Holdings

Leader Capital Holdings (LCHD) Forecast

Leader Capital Holdings (OTC:LCHD) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga